Olivier Danos - Regenxbio Chief Scientific Officer
| RGNX Stock | USD 9.92 0.09 0.90% |
Executive
Dr. Olivier Danos, Ph.D., is Chief Scientific Officer of the Company. He was our Chief Scientific Officer since March 2017. Prior to joining us, Dr. Danos was the Senior Vice President, Cell and Gene Therapy at Biogen Inc., a biotechnology company, from September 2014 until March 2017, where he led its gene therapy research and development activities. From September 2011 to September 2014, Dr. Danos was the Senior Vice President, Molecular Medicine, Synthetic Biology and Gene Regulation at Kadmon Pharmaceuticals. Prior to Kadmon, Dr. Danos served as the Director of the Gene Therapy Consortium of the University College of London and led a gene therapy research team at the Necker HospitalEnfants Malades in Paris. He also served as the Chief Scientific Officer at Genethon and Senior Director of Research at Somatix Therapy Corporationrationration, and held senior roles at the French National Centre for Scientific Research and the Pasteur Institute in Paris. Dr. Danos is the former President and founding member of the European Society of Gene and Cell Therapy since 2017.
| Age | 66 |
| Tenure | 7 years |
| Address | 9804 Medical Center Drive, Rockville, MD, United States, 20850 |
| Phone | 240 552 8181 |
| Web | https://www.regenxbio.com |
Regenxbio Management Efficiency
The company has return on total asset (ROA) of (0.2603) % which means that it has lost $0.2603 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7187) %, meaning that it created substantial loss on money invested by shareholders. Regenxbio's management efficiency ratios could be used to measure how well Regenxbio manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.48 in 2024. Return On Capital Employed is likely to rise to -0.57 in 2024. At this time, Regenxbio's Other Current Assets are fairly stable compared to the past year. Non Currrent Assets Other is likely to rise to about 8.4 M in 2024, whereas Total Assets are likely to drop slightly above 487 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| FACP MD | Protagonist Therapeutics | 65 | |
| Dr JD | 4D Molecular Therapeutics | 51 | |
| David MD | Immunocore Holdings | 53 | |
| An Song | 4D Molecular Therapeutics | N/A | |
| Colin Love | Replimune Group | 66 | |
| John III | Avidity Biosciences | 66 | |
| Pattie Chiang | Kezar Life Sciences | N/A | |
| Arthur Levin | Avidity Biosciences | 70 | |
| Jonathan Schwartz | Rocket Pharmaceuticals | 60 | |
| Emily Hill | Replimune Group | 44 | |
| Eileen Sawyer | Uniqure NV | N/A | |
| Jan Smith | Revolution Medicines | N/A | |
| Alan MD | Crinetics Pharmaceuticals | 61 | |
| Lily Hepworth | Immunocore Holdings | 41 | |
| Carena Spivey | Protagonist Therapeutics | N/A | |
| Andrew Schwendenman | Replimune Group | 48 | |
| Moriarty ESQ | Avidity Biosciences | 56 | |
| Aaron Ondrey | Rocket Pharmaceuticals | 48 | |
| Robert MD | Crinetics Pharmaceuticals | N/A | |
| Elly MD | Day One Biopharmaceuticals | N/A | |
| Sue Browne | Passage Bio | N/A | |
Management Performance
| Return On Equity | -0.72 | ||||
| Return On Asset | -0.26 |
Regenxbio Leadership Team
Elected by the shareholders, the Regenxbio's board of directors comprises two types of representatives: Regenxbio inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Regenxbio. The board's role is to monitor Regenxbio's management team and ensure that shareholders' interests are well served. Regenxbio's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Regenxbio's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kenneth Mills, CEO and President Director and Member of Disclosure Committee | ||
| Mitchell MBA, Executive CFO | ||
| Ram PharmD, Executive Operations | ||
| JD II, Executive Officer | ||
| Vittal Vasista, CFO, Sr. VP of Corporate Devel., Treasurer and Member of Disclosure Committee | ||
| Tricia Truehart, VP Communications | ||
| Olivier Danos, Chief Scientific Officer | ||
| Shiva Fritsch, Chief Officer | ||
| Curran MS, Executive COO | ||
| Dr JD, Executive Property | ||
| Andrew Yost, VP Devel | ||
| Stephen MD, Executive Officer |
Regenxbio Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Regenxbio a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.72 | ||||
| Return On Asset | -0.26 | ||||
| Profit Margin | (2.83) % | ||||
| Operating Margin | (2.57) % | ||||
| Current Valuation | 324.55 M | ||||
| Shares Outstanding | 49.55 M | ||||
| Shares Owned By Insiders | 7.39 % | ||||
| Shares Owned By Institutions | 92.25 % | ||||
| Number Of Shares Shorted | 4.62 M | ||||
| Price To Earning | 12.80 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Regenxbio Stock Analysis
When running Regenxbio's price analysis, check to measure Regenxbio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regenxbio is operating at the current time. Most of Regenxbio's value examination focuses on studying past and present price action to predict the probability of Regenxbio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regenxbio's price. Additionally, you may evaluate how the addition of Regenxbio to your portfolios can decrease your overall portfolio volatility.